Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Rectal Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
1 drug · 2 active trials
1 drug · 46 active trials
Data updated 17 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Capecitabine | Approved | Phase 3 | 46 | 22 | 21 | 124 | 1 | US | Apr 30, 1998 | 2000-10 |
| Adjuvant Chemotherapy | Phase 4 | Phase 4 | 2 | 2 | 1 | 5 | 0 | — | — | Jun 6, 2006 |
| Oxaliplatin | Phase 3 | Phase 3 | 38 | 21 | 17 | 111 | 0 | — | — | 1999-05 |
| Fluorouracil | Phase 3 | Phase 3 | 17 | 8 | 13 | 86 | 0 | — | — | 1997-05 |
| CAPOX Regimen | Phase 3 | Phase 3 | 14 | 5 | 8 | 23 | 0 | — | — | 2010-01 |
| Chemotherapy | Phase 3 | Phase 3 | 12 | 8 | 6 | 19 | 0 | — | — | Nov 3, 2009 |
| Bevacizumab | Phase 3 | Phase 3 | 9 | 5 | 9 | 52 | 0 | — | — | 2001-09 |
| FOLFOX Regimen | Phase 3 | Phase 3 | 9 | 3 | 2 | 15 | 0 | — | — | 2004-12 |
| Leucovorin | Phase 3 | Phase 3 | 7 | 4 | 9 | 53 | 0 | — | — | 1999-04 |
| Irinotecan | Phase 3 | Phase 3 | 7 | 2 | 5 | 41 | 0 | — | — | 1999-11 |
| Tislelizumab | Phase 3 | Phase 3 | 7 | 3 | 1 | 9 | 0 | — | — | Jun 22, 2020 |
| Cetuximab | Phase 3 | Phase 3 | 6 | 3 | 3 | 31 | 0 | — | — | 2003-12 |
| Serplulimab | Phase 3 | Phase 3 | 6 | 3 | 1 | 6 | 0 | — | — | Feb 22, 2023 |
| Immunotherapy | Phase 3 | Phase 3 | 3 | 0 | 1 | 4 | 0 | — | — | Nov 1, 2019 |
| Atezolizumab | Phase 3 | Phase 3 | 3 | 1 | 1 | 3 | 0 | — | — | Oct 22, 2019 |
| Celecoxib | Phase 3 | Phase 3 | 2 | 2 | 1 | 5 | 0 | — | — | 2000-03 |
| Chemoradiotherapy | Phase 3 | Phase 3 | 2 | 2 | 2 | 5 | 0 | — | — | 2005-09 |
| Pegfilgrastim | Phase 3 | Phase 3 | 0 | 0 | 1 | 2 | 0 | — | — | Feb 1, 2003 |
| Nivolumab | Phase 2 | Phase 2 | 12 | 1 | 0 | 18 | 0 | — | — | Aug 17, 2015 |
| Sintilimab | Phase 2 | Phase 2 | 7 | 5 | 0 | 9 | 0 | — | — | Aug 14, 2020 |
| Pembrolizumab | Phase 2 | Phase 2 | 4 | 2 | 0 | 8 | 0 | — | — | Jun 14, 2016 |
| Zanidatamab | Phase 2 | Phase 2 | 3 | 2 | 0 | 3 | 0 | — | — | Feb 15, 2023 |
| Ipilimumab | Phase 2 | Phase 2 | 2 | 1 | 0 | 7 | 0 | — | — | 2013-02 |
| Cyclophosphamide | Phase 2 | Phase 2 | 2 | 2 | 0 | 6 | 0 | — | — | 2012-02 |
| Aldesleukin | Phase 2 | Phase 2 | 2 | 2 | 0 | 5 | 0 | — | — | 2000-07 |
| Camrelizumab | Phase 2 | Phase 2 | 2 | 1 | 0 | 5 | 0 | — | — | Nov 10, 2019 |
| Trastuzumab | Phase 2 | Phase 2 | 2 | 1 | 0 | 5 | 0 | — | — | Aug 17, 2015 |
| Fludarabine | Phase 2 | Phase 2 | 2 | 2 | 0 | 4 | 0 | — | — | Sep 21, 2017 |
| Encorafenib | Phase 2 | Phase 2 | 2 | 0 | 0 | 3 | 0 | — | — | Jun 14, 2019 |
| Raltitrexed | Phase 2 | Phase 2 | 2 | 1 | 0 | 3 | 0 | — | — | 2006-12 |
| Tucatinib | Phase 2 | Phase 2 | 2 | 2 | 0 | 3 | 0 | — | — | Dec 30, 2022 |
| Cabozantinib | Phase 2 | Phase 2 | 2 | 0 | 0 | 2 | 0 | — | — | Jun 23, 2021 |
| Regorafenib | Phase 2 | Phase 2 | 1 | 0 | 0 | 11 | 0 | — | — | 2014-10 |
| FOLFIRI Regimen | Phase 2 | Phase 2 | 1 | 1 | 0 | 5 | 0 | — | — | 2004-12 |
| Dasatinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 4 | 0 | — | — | 2007-07 |
| Fruquintinib | Phase 2 | Phase 2 | 1 | 1 | 0 | 3 | 0 | — | — | Dec 11, 2017 |
| Pertuzumab | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | 2007-10 |
| Temozolomide | Phase 2 | Phase 2 | 1 | 1 | 0 | 3 | 0 | — | — | May 10, 2013 |
| Toripalimab | Phase 2 | Phase 2 | 1 | 1 | 0 | 3 | 0 | — | — | Sep 1, 2022 |
| Trametinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | Nov 26, 2012 |
| Binimetinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
| Immunomodulatory Oligonucleotide | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Jan 25, 2022 |
| Palbociclib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | 2009-10 |
| Abemaciclib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Dec 2, 2020 |
| Adavosertib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Adebrelimab | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Jan 1, 2024 |
| Afatinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Capivasertib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Copanlisib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Crizotinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.